Tender Details

Country: USA
Summary: Completion of FDA Project - Development of a Model that Integrates Inflammation and Tissue Injury to Predict and Mitigate the Post-Acute of COVID19
UST Ref No: 125931773
Deadline: 12 Sep 2025
Financier: Self Financed
Purchaser Ownership: Government
Tender Value: Refer Document
Notice Type: Tender
Document Ref. No.: FDA-OC-25-130611
Purchaser's Detail:
Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details. Login to see full purchaser details.
Login to see details
Description:
Description
People infected with SARS-CoV-2 (the virus that causes COVID-19) typically recover within a few days or weeks. However some individuals have long-term effects that persist for multiple weeks, months, or even years; this is known as post-COVID conditions (PCC) or long COVID. In such cases, people experience both obvious and subtle long-term health consequences after recovering from the active infection.
While PCC occurs more frequently in people who have had severe COVID-19 illness, individuals experiencing these health consequences are not limited those who were the sickest. These effects manifest in patients across the full spectrum of COVID-19 severity and ages, including children.
At this time, it is not possible to identify patients who will develop PCC during the active phase of COVID-19 infection. If it were possible to identify patients who are more susceptible to suffering long-term health consequences of SARS-CoV-2 infection, then it may be possible to mitigate those outcomes with medical interventions. While considerable efforts have gone into understanding how COVID-19 affects the body in adults, much less is known about how COVID-19 affects children, and how those effects manifest into long-term health consequences of COVID-19 infection.
Research to develop both pediatric and adult models of PCC/long COVID was original funded by FDA Office of the Chief Scientist/Office of Regulatory and Emerging Science (OCS/ORES) in 2022. However, due to an administrative error, the contract ended prior to work completion and final reporting/analysis. Given the success of the technical approach to date and the value of preliminary data, among other factors, FDA has determined the criticality to complete the project. As such, this contract will support completion of final deliverables by the performer.
Documents:

Requirements-Document-FDA-OC-25-OC130611.pdf

If you are registered member, kindly login to view full details of this tender notice:

Completion of FDA Project - Development of a Model that Integrates Inflammation and Tissue Injury to Predict and Mitigate the Post-Acute of COVID19 - USA Tender

The HEALTH AND HUMAN SERVICES, DEPARTMENT OF | FOOD AND DRUG ADMINISTRATION, a Government sector organization in USA, has announced a new tender for Completion of FDA Project - Development of a Model that Integrates Inflammation and Tissue Injury to Predict and Mitigate the Post-Acute of COVID19. This tender is published on USARFP under UST Ref No: 125931773 and is categorized as a Tender. Interested and eligible suppliers are invited to participate by reviewing the tender documents and submitting their bids before the deadline on 2025-09-12.

The estimated tender value is Refer Document, and full details, including technical specifications and submission requirements, are provided in the official tender documents. Ensure all submissions meet the criteria outlined to be considered for evaluation.